Celcuity (CELC) Other Accumulated Expenses (2018 - 2025)
Celcuity (CELC) reported Other Accumulated Expenses of $20.9 million for Q4 2025, up 280.96% on a YoY basis from $5.5 million in Q4 2024, and up 280.96% quarter-over-quarter from $5.5 million in Q4 2024.
Celcuity (CELC) Other Accumulated Expenses (2018 - 2025) Analysis & Trends
Celcuity has reported Other Accumulated Expenses for 4 years, with the latest figure at $20.9 million in Q4 2025.
- For the quarter ending Q4 2025, Other Accumulated Expenses rose 280.96% year-over-year to $20.9 million; the trailing twelve-month figure through Dec 2025 stood at $20.9 million (up 280.96% YoY), and the FY2025 full-year result was $20.9 million, up 280.96% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $20.9 million, up from $5.5 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $20.9 million in Q4 2025, with the low at $5.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.87 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Dec 31, 2019 | 112,746.00 |
| Dec 31, 2018 | 52,347.00 |